NCT04309929 is a clinical trial of Analgesics in Breast Cancer, sponsored by Careggi Hospital.

Who is sponsoring NCT04309929?

NCT04309929 is sponsored by Careggi Hospital.

What drugs are being tested in NCT04309929?

Interventions in NCT04309929: Analgesics.

What condition does NCT04309929 study?

NCT04309929 studies Breast Cancer.

Is NCT04309929 still recruiting?

NCT04309929 is currently completed. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT04309929

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Description of the Analgesia Obtained With the Anesthesiological Protocols Currently Used in Breast Surgery

Completed Last updated 17 March 2020

What this trial tests

trial testing Analgesics in Breast Cancer in 200 participants. Completed in 31 July 2018.

Timeline

12 September 2016

Primary endpoint
31 July 2018

31 July 2018

Quick facts

Lead sponsor	Careggi Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	200
Start date	12 September 2016
Primary completion	31 July 2018
Estimated completion	31 July 2018
Sites	1 location across Italy

Drugs / interventions tested

Analgesics — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Careggi Hospital

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to describe the pain-relieving effect obtained with the current post-surgery pain control methods used in breast surgery by measuring the painful sensation and the consumption of opioids in the first 24 post-surgery hours. It also aims to describe the appearance of any complications such as post-surgery nausea and vomiting. Current anesthesia involves the combined use of intravenous painkillers and anti-inflammatory drugs such as acetaminophen, ketorolac, tramadol or morphine (the latter via PCA system = patient-controlled analgesia) or for local administration at the surgical site level ( local anesthetics). It is also proposed to describe the intensity and interference of pain in daily activities

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Chronic pain after breast surgery: incidence, associated factors, and impact on quality of life, an observational prospective study.
Villa G, Mandarano R, Scirè-Calabrisotto C, Rizzelli V, et al · · 2021 · cited 16× · PMID 33622393 · DOI 10.1186/s13741-021-00176-6
Chronic pain after breast surgery: incidence, associated factors and impact on quality of life, an observational prospective study
Villa G, Mandarano R, Calabrisotto CS, Rizzelli V, et al · · 2021 · DOI 10.21203/rs.3.rs-53287/v4

Verify or expand the search:

Other trials of Analgesics

Trials testing the same drug.

NCT05322603 — Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia · NA · completed
NCT04541147 — Opioid & Steroid Use Following Tonsillectomy in Pediatric Patients · Phase 4 · terminated
NCT03639389 — Postoperative Pain, Recovery and Discharge Following Robot-assisted Laparoscopic Prostatectomy · Phase 3 · completed
NCT03862391 — Does Low Flow Anesthesia Reduce Postanaesthetic Emergence Agitation? · Phase 4 · completed
NCT03534869 — Auricular Acupuncture as Effective Pain Relief After Episiotomy · Phase 3 · completed

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Careggi Hospital trials

Trials by the same sponsor.

NCT04580680 — Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT) · recruiting
NCT04033224 — Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure · recruiting
NCT03807414 — Development of a Web-based Multicenter Registry on the Use of oXiris Membrane for EBPTs in Critically Ill Patients · active not recruiting
NCT04341974 — Perioperative Use of Serum Creatinine and Postoperative Acute Kidney Injury · completed
NCT03820232 — Intraoperative Body Core Temperature Monitoring: Oesophageal Probe vs Heated Controlled Servo Sensor · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04309929 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Careggi Hospital
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04309929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing